Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones

January 4, 2024

https://www.globenewswire.com/news-release/2024/01/04/2803829/33090/en/Axsome-Therapeutics-Provides-Preliminary-Fourth-Quarter-and-Full-Year-2023-Net-Revenue-and-2024-Anticipated-Milestones.html

Preliminary total 4Q and full year 2023 net product revenue of $71 million and $204 million, respectively

Auvelity preliminary 4Q and full year 2023 net product sales of $49 million and $130 million, respectively

Read more at globenewswire.com

Related news for (AXSM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.